Additional file 5: of Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

Figure S5. Kaplan-Meier analysis of overall survival (OS) calculated from the date of initial pathologic diagnosis of SCLC in the immunotherapy-treated cohort. (DOCX 89 kb

Supplementary Figure 1 from Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

Pathways targeted by the Dana-Farber Targeted Therapy Collection and clinical development status</p

Supplementary Table S1 from Clinical, Pathologic, and Biologic Features Associated with <i>BRAF</i> Mutations in Non–Small Cell Lung Cancer

Supplementary Table S1 - XLS file 32K, Baseline characteristics of the patients with driver alterations in EGFR, KRAS or ALK</p

Supplementary Figure 4 from Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

Chemical structures of lead compounds</p

Supplementary Figure 2 from Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

Comparison of compound libraries reported in ROS1 kinase screens</p

Supplementary figure legends from Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

Legends to the supplementary figures</p

Supplementary file 1 from Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

Contents of the Dana-Farber Targeted Therapy Library and raw data</p

Supplementary Figure 3 from Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

Inhibition of Ba/F3 CD74-ROS1 proliferation</p

Supplementary Figure 5-7 from Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

Inhibition of ROS1 signaling in Ba/F3 and UMG-118 cells and the RNPC3-ROS1 fusion</p

Supplementary Data from Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer

Supplementary Material</p